.. Celgene acquires Avila Therapeutics Celgene Corporation today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon specific milestones linked to AVL-292 and applicants from Avila’s discovery system. Related StoriesDiscovery can offer clues to how some infections control expression of genetic materialGriffith University uncovers first 3-D picture of protein linked to cancer tumor spreadLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. The Avilomics study team brings to Celgene a thrilling clinical applicant in AVL-292, along with a dynamic system of protein silencing which has incredible potential, stated Tom Daniel, M.D., EVP, President of Early and Study Development for Celgene.GSK has donated over 440 million albendazole tablets to date, which serve as a cornerstone of the program. Related StoriesResearchers receive Bill & Melinda Gates Basis grant to eliminate neglected tropical diseasesDeaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMECancer medical diagnosis improvements in England: an interview with Lucy Elliss-BrookesJP Garnier, CEO of GlaxoSmithKline added, The Egypt data show that we can now eliminate an illness which has plagued the world for years and years. We remain committed to donating as much albendazole as required to remove this disabling disease, but ultimate success depends on continuing long-term commitments by all partners across the globe.